Comments
Description
Transcript
Francesco Maria Senatore
Il Polo senese ed il Distretto regionale scienze della vita nella prospettiva europea Dr. Francesco Maria Senatore Business Development Toscana Life Sciences Foundation TLS 2013 Argomenti • • • • • TLS 2013 Polo Senese: TLS Distretto: Cluster Regionale Il mercato della Salute in Europa Le necessità delle imprese Evoluzione del Cluster www.toscanalifesciences.org TLS 2013 TLS Mission MPS Public Institutions University Applied Research Results Industrial Development Territory TLS 2013 Siena - The Science Park Monothematic : Life Sciences (Red Biotech) drugs diagnostics medical devices biomedical technologies Laboratories, offices, equipment and utilities Consulting services and support Access to public and private financing tools JCVI April 2012 Science Park Location: Siena - Novartis site Total surface area: 83.000 sq. mt. Total buildings surface: 38.400 sq. mt. Labs (research/devel./Q.A.): 8.200 sq. mt. Production plants: 6.800 sq. mt. Warehouses: 2.800 sq. mt. Offices: 8.400 sq. mt. Services: 4.700 sq. mt. TLS bio-incubator Industrial and academic research activities Center of excellence for Novartis Vaccines More than 470 researchers Common facilities, services and utilities JCVI April 2012 TLS Bio-incubator 10 laboratory modules (ranging from 60 to 140 m2) fully equipped according to company’s needs GMP facility for medicinal products derived from human blood or plasma (160 m2) Analytical labs and common services (135 m2) BSL 3 lab Animal care facility Offices, meeting rooms (600 m2) JCVI April 2012 TLS - Main Incubation Services Intellectual property protection consultancy Technology Transfer/Start-up Creation Business development coaching Grants search and application support Scouting of industrial and financial partners Bio-partnering support Infrastructure Services (Front office, meeting room, etc.) Dedicated scientific equipment up to € 200k Common high-tech equipment and facilities JCVI April 2012 Incubation Deal-Flow: the ”Picking the Winner Approach” International Call for Application Business Plan submission Project selection TLS Executive Board approval Find Start up financing Incubation JCVI April 2012 TLS Evaluation Committee Dr. Andy Richards, Cambridge (UK) Prof. Stephen Hanessian, Montréal (CA) Dr. Elkan Gamzu, Boston (USA) JCVI April 2012 Dr. Bertil Samuelsson, Stockholm (SE) Dr. Eva Pisa, Stockholm (SE) Torre Fiorentina Campus – September 2005 JCVI April 2012 Companies and Research Groups 2013 TLS 2013 TLS Performance Indicators 2007 2010 2011 2012 10 - 70 93 112 15 48 63 Patent Applications 8 25 22 24 Granted Patents 5 24 25 27 Collab./Agreem./Licensing 34 48 66 Diagnostics Prototypes 8 - 6 8 23 Compounds in Clinical Phases - 1 - 2 Products on the Market 1 - 12M 25M 32.7 M 22 44.0 M - - 1.5 M 3.1 M Employees Scientific Publications Investments Attraction Companies Revenue TLS 2013 TLS Incubated Companies & Research Groups: Total Financial Resources Companies and Research Groups Financial Resources (2011) Stakeholders Investment Local Seed Funds Regional Seed Funds Other Funds Grants TOTAL JCVI April 2012 Companies 17.879.159 6.280.000 2.350.000 2.350.000 8.609.809 37.468.967 % 47,7 16,7 6,3 6,3 23 100 Companies & Research Group 18.689.159 6.280.000 2.350.000 2.350.000 14.354.409 44.023.567 % 42,5 14,3 5,3 5,3 32,6 100 TLS 2013 Universities and Research Centers JCVI April 2012 Tuscany -Health Care System Quality “33,9% of total clinical trials carried out in Italy are performed in Tuscany” JCVI April 2012 Some Big Players TLS 2013 Tuscany is a strategic region in the Life Science Companies Tuscany % Tuscany Biotech 221 30 14 Pharma 198 20 10 2.735 156 6 Medical Devices Turnover ( € Mil .) Biotech Italy Tuscany % Tuscany 7.157 1.630 23 Pharma 25.000 3.300 13 Medical devices 16.800 811 5 10.940 645 6 Pharma Services TLS 2013 Italy TLS 2013 Affiliated Companies Employees R&D Employees Turnover in € Mil. Labs square meters Patents 104 10.646 1.376 5.233 31.203 775 The Tuscany Life Science Cluster National & international clusters Public Institutions Tuscany Life Sciences Cluster Steering Committee Member Representatives Committee Services Needs Entrepreneurial System TLS 2013 EU Healthcare Market Organisation for Economic Cooperation and Development (OECD) www.oecd.org/ TLS 2013 TLS 2013 •Growth in health spending per capita slowed or fell in real terms in 2010 in almost all European countries, reversing a trend of steady increases. •Spending had already started to fall in 2009 in countries hardest hit by the economic crisis but this was followed by deeper cuts in 2010 in response to growing budgetary pressures and rising debtto-GDP ratios. •On average across the EU, health spending per capita increased by 4.6% per year in real terms between 2000 and 2009, followed by a fall of 0.6% in 2010. TLS 2013 TLS 2013 •Reductions in public spending on health were achieved through a range of measures, including reductions in wages and/or employment levels, increasing direct payments by households for certain services and pharmaceuticals, and imposing severe budget constraints on hospitals. •Gains in efficiency have also been pursued through mergers of hospitals or accelerating the move from inpatient care to outpatient care and day surgery. TLS 2013 •The public sector is the main source of health care financing in all European countries. •In 2010, nearly three-quarter (73%) of all health spending was publicly financed on average in EU member states. •Public financing accounted for over 80% in the Netherlands, the Nordic countries (except Finland), Luxembourg, the TLS 2013 Service support to Life Science SME TLS 2013 Internazionalization is a challenge for SMEs TLS 2013 SME’s support need for foreign markets • Align your product portfolio to the markets with high growth potential (market Analysis) • Develop market-entry and market-expansion strategies by identifying the regions and market segments poised for strong growth (Strategic Positioning) • Create a more tailored country strategy through the understanding of market outlook and major trends (local link) • Develop key strategic initiatives by understanding the key focus areas and top-selling products of leading companies (match making events) TLS 2013 Internationalization support Deep insight into companies’ needs Framework agreements with institutional partners Network of selected and qualified partners Networking Europe’s Biocommunities TLS 2013 ALISEI, Cluster nazionale Scienze della Vita “Advanced LIfe SciEnces in Italy” National Technology Cluster Call • • • a) b) c) d) • The MIUR (Ministry of Education, Universities and Research) published a call for the creation of 9 National Technological Clusters corresponding to different high tech sectors, one of them is Life Science For each sector only a single cluster has been created Each Cluster presents 4 R&D projects Total costs in between 10 and 12 millions of euro A maximum of 8 proponents Industrial partners covering at least the 50% of costs, with SME’s covering at least the 15% Public partners covering at least the 35% of costs The MIUR supports the call with 368 millions of euro, 63 millions as a contribution to the costs and 305 as subsidized credit. Moreover the MIUR allocates additional 40 millions of euro of contribution for projects involving Puglia, Calabria, Sicilia and Campania regions. Perchè un Cluster • • • • Nuove dinamiche di sviluppo verso le economie basate sulla conoscenza e l’innovazione. Tra i fattori in grado di sostenere e promuovere la transizione vi sono le “reti di conoscenza”. In linea con iniziative a livello europeo, come la Strategia di Lisbona e la “Europe 2020 Growth Strategy”, nella logica di un recupero di competitività grazie allo sviluppo di un’economia basata sulla conoscenza e sull’innovazione. Una delle criticità che si intende superare con il Cluster è rappresentata dalla frammentazione delle iniziative nell’ambito Scienze della Vita: senza adeguata massa critica mancano effettive ricadute per l’intero sistema Paese. L’ambizione è quella di favorire l’aggregazione di risorse non solo a livello regionale, ma anche tra i poli di riferimento nazionali e di entrare nelle grandi reti di aggregazione europee, partecipando ai “mega cluster” transnazionali che connettono i nodi specializzati esistenti in ciascun Paese (“Biotechnology strategy and action plan” della Commissione Europea ) ALISEI - gli attori • ALISEI raccoglie strutture produttive e di ricerca, individuali e aggregate, appartenenti a 12 Regioni • In ALISEI sono rappresentate le Associazioni di categoria: Assobiomedica, Assobiotec, Farmindustria e vi partecipa il sistema pubblico della ricerca: CNR, ENEA, ICE, IIT • La governance di ALISEI è aperta, per accogliere ulteriori componenti scientifiche, industriali e istituzionali coerenti con la sua missione ALISEI: Cluster Strategic positioning • Vision: To be a driving force in the economic growth of Italian regions in the field of human health • Mission: To establish a national network of skills and capacities of research, innovation and industrial development in the Life Science sector with the aim of answering the social and economic challenges in the field of human health • Timeline: At least 5 years • a) b) c) Macrotrends: Personalized approach and integration between therapy and diagnosis Ageing and chronic diseases Convergent technologies The future Geographical Area International Level Mega Cluster European Level National level Super Cluster Regional level Cluster Local level Science Park [-] Virtual cluster integration [++] Relevance of geographical proximity Fonte: TLS elaboration from Sternberg (2003) TLS 2013 [++] [-] Thank you Francesco Maria Senatore Business Development Communication & Projects Tuscany Life Science Cluster & Foundation Via Fiorentina, 1 53100 Siena ITALY Tel.: +39 0577 231207 Mobile:+39 340 0917237 Fax: +39 0577 43444 [email protected] www.toscanalifesciences.org TLS 2013 Conclusions • International visibility is key for R&D intensive and startup companies • International presence is key for mature/expansion companies • Both types of SME can’t approach the market alone • Science Parks and Cluster organizations play a very important role in building up a real international network is key and should go beyond the EU TLS 2013 National Cluster ranking 41 41 TLS 2013 Post-Incubation Building TLS 2013 International Benchmarking TLS 2013 Biotech clusters in US Cluster Companies Bay Area - San Francisco (California) 715 Maryland 350 San Diego (California) 240 Boston (Massachusetts) 220 Philadelphia (Pennsylvania) 135 From V. Chiesa – Bioforum, Milano 2007 FM Senatore Bio-Europe 46 Biotech clusters in EU Cluster Companies Cambridge (UK) 422 Biovalley (France – Germany – Switzerland) 320 Munich (Germany) 150 Heidelberg (Germany) 121 Berlin – Brandeburg (Germany) 115 Medicon Valley (Sweden – Denmark) 110 Edinburgh Dundee Glasgow (UK) 75 Oxford (UK) 85 Evry – Ile de France (France) 54 From V. Chiesa – Bioforum, Milano 2007 FM Senatore Bio-Europe